MTRI · InMed Pharmaceuticals Inc. · Documents

$18.79 +0.44 (+2.37%) Q4 2021 earnings call transcript

Market Cap

$8.58M

549,374

Volume · Nov 13 7698 Avg daily vol (6 sessions) 62.9K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2026 Net loss $12.56M 10-K filed Sep 9, 2026 Quarterly report FY2027 Q1 Net loss $2.33M 10-Q filed Nov 3, 2026 Latest results New Financial results 8-K filed Nov 10, 2026 Earnings call Q4 2021 earnings call Held Jun 30, 2021

2026

Nov 10

Current report 8-K Events of Nov 6

Entered into a material agreement, Completed an acquisition or sale of assets, Financial results, Unregistered sale of equity, Change to shareholders' rights, Change in control, Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change, Code of ethics change or waiver, Change in shell company status AI summary on its way

Nov 9

Current report 8-K

Merger closes with approximately $490 million financing

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. after raising approximately $490 million in gross proceeds; shares began trading on Nasdaq under MTRI on November 9, 2026.

Regulation FD disclosure

2 source passages

Mentari Therapeutics, Inc. (“Mentari” or the “Company”), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced completion of the previously disclosed merger with InMed Pharmaceuticals Inc. (“InMed”). The combined company will operate under the name Mentari Therapeutics, Inc., and its shares will begin trading on the Nasdaq Capital Market today, November 9, 2026, under the name “Mentari Therapeutics, Inc.” and the ticker symbol “MTRI.” Immediately prior to the closing of the merger, Mentari completed previously announced private financings totaling approximately $490 million in gross proceeds Open the document at this passage

Nov 5

Current report 8-K Events of Nov 4

Shareholders approve proposals as name change and consolidation take effect

InMed Pharmaceuticals Inc., now Mentari Therapeutics, Inc., reported that shareholders approved all proposals on November 4, 2026, including Nevada redomestication. The company completed a one (1)-for-ten (10) share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.

Regulation FD disclosure

5 source passages

Vancouver, British Columbia - November 4, 2026. InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) (NASDAQ: INM) Each item of business voted on at the Meeting was approved by the shareholders. The approval of the Redomestication Proposal approved, via special resolution, the redomestication of the Company from British Columbia, Canada to the State of Nevada by continuation out of British Columbia under British Columbia law and domestication under Nevada law. The Company is also pleased to announce that, following the Meeting, it has completed the previously announced consolidation of its Common Shares on the basis of one (1) post-consolidation Common Share for each ten (10) pre-consolidation Common Shares (the "**Consolidation**"). As of November 4, 2026, immediately prior to the completion of the Consolidation, there were 5,493,735 Common Shares issued and outstanding in the capital of the Company. Following the completion of the Consolidation, there were approximately 549,374 Common Shares issued and outstanding. Open the document at this passage

Nov 5

Current report 8-K Events of Nov 4

Share consolidation precedes Nevada redomestication and merger

InMed Pharmaceuticals Inc. legally changed its name to Mentari Therapeutics, Inc. on November 4, 2026 and completed a one (1)-for-ten (10) common share consolidation. Shareholders approved merger-related issuance, redomestication to Nevada, and related proposals.

Charter or bylaw amendment, or fiscal year change, Shareholder vote results, Other events Read from the first part of this long document

4 source passages

On November 4, following the Shareholders Meeting, 2026, the Company filed a notice of alteration (the “Notice of Alteration”) with the Province of British Columbia Registrar of Companies to change the name of the Company from “InMed Pharmaceuticals Inc.” to “Mentari Therapeutics, Inc.,” effective as of November 4, 2026 (the “Name Change”). As of the effective time of the Consolidation, every ten (10) Common Shares issued and outstanding immediately prior to the Consolidation were automatically consolidated into one (1) issued and outstanding Common Share, without any change in shareholders’ proportionate equity or voting interests in the Company, other than as a result of the treatment of fractional shares described below. The Company’s shareholders approved (i) the issuance of the Common Shares, including the Common Shares issuable upon conversion of the Series A Preferred Shares, which will represent more than 20% of the Common Shares outstanding immediately prior to the First Merger, to stockholders of Mentari pursuant to the Merger Agreement, and (ii) the change of control of the Company resulting from the First Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. The Company’s shareholders approved, via special resolution, the redomestication of the Company from British Columbia, Canada to the State of Nevada by continuation out of British Columbia under British Columbia law and domestication under Nevada law. Open the document at this passage

Nov 3

Current report 8-K

Merger financing supports operations into 2029

InMed Pharmaceuticals Inc. expects its merger with Mentari Therapeutics to close in the fourth quarter of calendar 2026, supported by approximately US$490 million in financing intended to fund operations into 2029; Nasdaq granted until March 15, 2027 to regain equity compliance.

Regulation FD disclosure

4 source passages

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company") The proposed merger is expected to close in the fourth quarter of calendar 2026, subject to the satisfaction or waiver of the remaining closing conditions, including the required shareholder approvals. Mentari has announced private placements totaling approximately US$490 million in expected aggregate gross proceeds in connection with the transaction. This financing is expected to support operations into 2029, including through Phase 2a readouts for both of Mentari's lead PACAP-targeted programs. Nasdaq indicated that it had accepted the compliance plan, and determined that InMed has until March 15, 2027, to regain compliance with Nasdaq Listing Rule 5550(b)(1). Open the document at this passage

Nov 3

Quarterly report 10-Q FY2027 Q1, ended Sep 30

Mentari Financing Could Restore Nasdaq Compliance

InMed expects its Mentari merger, backed by approximately $490.0 million in pre-closing financing, to restore Nasdaq equity compliance; however, cash was $1.1 million and substantial doubt about going concern remains.

Net loss $2.33M Diluted EPS -$0.42

Read from the MD&A section

4 source passages

As a result of Mentari’s pre-closing financing, the combined company is expected to receive aggregate gross proceeds of approximately $490.0 million (including $50.0 million of proceeds previously received by Mentari from the issuance of convertible notes and accrued interest on such notes). Accordingly, InMed expects that the closing of the Merger will result in InMed regaining compliance with the minimum shareholders’ equity requirement. As of the issuance date of these condensed consolidated financial statements, we expect our cash, cash equivalents and short-term investments of approximately $1.1 million as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of calendar 2026, depending on the level and timing of our operating expenses. We have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. Open the document at this passage

Sep 29

Registration statement S-4/A

Registration statement

InMed Pharmaceuticals Inc. proposes to merge with Mentari Therapeutics, Inc., redomesticate from British Columbia, Canada to Nevada and rename itself Mentari Therapeutics, Inc.; Mentari holders are expected to own approximately 99.03% of the combined company on a fully-diluted basis.

Read from the first part of this long document

Sep 18

Current report 8-K Events of Sep 16

Delisting notice or listing transfer, Other events AI summary on its way

Sep 9

Registration statement S-4/A

Registration statement AI summary on its way

Sep 9

Annual report 10-K FY2026, ended Jun 30

Annual report for FY2026 AI summary on its way

Net loss $12.56M Diluted EPS -$3.12

Jul 22